Mesa Labs reported its financial results for the third quarter ended December 31, 2025. Revenues for the quarter reached USD 65.13 million, a 3.6 percent increase. Gross profit for the period was USD 41.80 million. Operating income for the third quarter was USD 7.98 million, representing a 38 percent increase. For the nine months ended December 31, 2025, revenues were USD 185.41 million, while gross profit totaled USD 116.07 million. The company’s non-GAAP organic and core organic revenues grew 3.6 percent and 1.2 percent, respectively, in the third quarter. Non-GAAP organic revenue growth, excluding CG China revenues, was 5.7 percent. Non-GAAP adjusted operating income, excluding unusual items, increased 15.4 percent and was 26.2 percent of revenues for the quarter. Mesa Labs also reported repayment of USD 8.7 million of debt during the quarter, reducing its total net leverage ratio to 2.62. Mesa Labs is a global provider of life science tools and quality control solutions for the pharmaceutical, healthcare, and medical device industries. The company highlighted its ongoing efforts to support product integrity, patient and worker safety, and quality of life improvements worldwide.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Mesa Laboratories Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 9647379) on February 03, 2026, and is solely responsible for the information contained therein.